Floatz logo

AVEXITIDE

Obesity

Vanderbilt University Medical Centerprotein_peptidePhase 4 / ApprovedDormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
59/ 100

Competitive context

575 Active assets in the Obesity cohort.

Asset / SponsorPhaseRating
vi-0521
VIVUS LLC
Phase 4BBB
Tirzepatide
LABORATORIOS INDUFAR
Phase 4BBB
Efsubaglutide Alfa
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 4BBB
Phentermine
Russell McCulloh, MD
Phase 4BBB
Deoxycholic Acid
University of California, San Diego
Phase 4BBB

View all 50 →

Same molecule, other indications

AVEXITIDE is also rated in:

prediabetes syndromeDormant
BB
Indicative ·
68 / 100
View asset →
hyperinsulinemic hypoglycemiaDormant
CC
Indicative ·
47 / 100
View asset →
glucose metabolism diseaseDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →